SRRT and hepatocellular carcinoma: Recently, Ars2 was found to be overexpressed in human cholangiocarcinoma and hepatocellular carcinoma (HCC) and therefore considered as a diagnostic and prognostic marker, as well as a potential target for therapeutic intervention in cancer [15–17].